News Release

Multimodal analgesia: The new 'standard of care' for pain control after total joint replacement

Peer-Reviewed Publication

Wolters Kluwer Health

July 8, 2021 - Until relatively recently, opioids were a mainstay of treatment for pain following total hip or knee replacement. Today, a growing body of evidence supports the use of multimodal analgesia - combinations of different techniques and medications to optimize pain management while reducing the use and risks of opioids, according to a paper in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

"Multimodal analgesia has become the standard of care for total joint arthroplasty as it provides superior analgesia with fewer side effects than opioid-only protocols," write Javad Parvizi, MD, FRCS, of Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, and coauthors. They provide an update on multimodal analgesia for patients undergoing total joint arthroplasty (TJA), including the protocol utilized at their institution.

Following TJA, combination techniques improve pain control - and reduce opioid risks

Good pain management is critical to achieving the best possible outcomes in hip or knee replacement. Traditionally, pain following TJA was treated with opioid-based regimens, especially patient-controlled analgesia with intravenous opioids. However, opioids have substantial adverse effects, including confusion, nausea and vomiting, and respiratory depression - in addition to the well-known risks of opioid addiction, abuse, and misuse.

"Multimodal analgesia involves the use of various agents with different mechanisms of action, thus maximizing benefit while minimizing side effects," Dr. Parvizi and colleagues write. Although the exact medications and techniques may vary by hospital, multimodal combinations are now preferred over opioid-based approaches.

Ideally, multimodal analgesia starts before surgery and continues during and after the procedure, including after the patient is discharged from the hospital. Recent studies have shown that multimodal analgesia can improve pain scores and side effects while reducing opioid use, compared to opioid-based regimens.

In their review, Dr. Parvizi and coauthors provide an update on the use of multimodal analgesia for TJA, including:

  • Analgesic Medications. Familiar drugs with good safety characteristics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, which provide excellent pain control. Other useful medications include certain antiseizure medications, which are typically used for the treatment of nerve pain, and corticosteroids such as dexamethasone, which are highly effective in reducing inflammation. The "weak" opioid drug tramadol is sometimes used, although questions remain about its safety.
  • Local Anesthetics. Multimodal analgesia may also include various local anesthetic techniques. These include anesthetics given via local infiltration: similar to local anesthesia for dental procedures, these techniques prevent pain by numbing the nerves in a specific area. Local anesthetics can also be used to perform specific types of nerve blocks, especially for knee replacement surgery.
  • Nondrug Strategies. Nonpharmacologic techniques such as electrotherapy, acupuncture, or cryotherapy, which can be as simple as applying an ice pack, have shown promising results. However, there are questions about the quality of the current studies on these modalities. New surgical techniques, such as those that avoid the use of a tourniquet, may help reduce the need for opioids.

Dr. Parvizi and coauthors look at some emerging treatments for pain control, such as the local delivery of pain medications via implants, a procedure using cold to temporarily block pain transmission by nerves (cryoneurolysis), and the stimulation of peripheral nerves. Cannabis is being explored as a possible multimodal treatment, although studies so far have shown no reduction in pain or opioid use after TJA.

The article includes a table summarizing the Rothman Institute protocol for multimodal analgesia for TJA - from pre-emptive analgesia before surgery through follow-up care after discharge. Dr. Parvizi and colleagues conclude, "[M]ultimodal pain management is essential to guarantee proper perioperative pain control in TJA and optimize surgical outcome and postoperative recovery, while minimizing the use of opioids."


Click here to read "An Update on Multimodal Pain Management After Total Joint Arthroplasty."

DOI: 10.2106/JBJS.19.01423

About The Journal of Bone & Joint Surgery

The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.